Irinotecan Actavis (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is converted inside cells to the active metabolite SN‑38. SN‑38 binds to the DNA‑topoisomerase I complex and prevents the re‑ligation of single‑strand DNA breaks during replication. This leads to accumulation of DNA damage, triggering apoptosis in rapidly proliferating cancer cells.

The dose of Irinotecan Actavis is individualized by the prescribing oncologist based on factors such as the patient’s body surface area, type and stage of cancer, renal and hepatic function, and prior treatment history. No fixed dosing schedule can be provided without a medical prescription.

Safety data for Irinotecan in pregnancy and lactation are limited, and the drug is generally contraindicated because of potential fetal toxicity and excretion in breast milk. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To order Irinotecan Actavis, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including cold‑chain if required) and assists with import documentation.

Irinotecan and topotecan are the two main topoisomerase I inhibitors used in oncology. Irinotecan is typically administered intravenously and is preferred for colorectal and certain lung cancers, while topotecan is available in both intravenous and oral forms and is often used for ovarian and small‑cell lung cancers. Differences in pharmacokinetics, toxicity profiles, and approved indications guide the choice between them.

Irinotecan Actavis should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. The solution must be prepared in a sterile environment and used within the time frame recommended by the manufacturer. Personnel handling the product should wear appropriate protective equipment to avoid accidental exposure.

Irinotecan Actavis is given as an intravenous infusion, typically over 30 to 90 minutes depending on the regimen. The infusion is performed in a clinical setting by qualified healthcare professionals, with monitoring for infusion‑related reactions and supportive care measures such as anti‑emetics and hydration as needed.

The most serious adverse events associated with Irinotecan include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhea or colitis, hepatic toxicity, and rare but severe allergic reactions such as anaphylaxis. Patients should be educated to report fever, persistent diarrhea, abdominal pain, jaundice, or any signs of an allergic response immediately.

Irinotecan is contraindicated in patients with known hypersensitivity to the drug or its excipients. It should be avoided in individuals with uncontrolled infections, severe bone‑marrow suppression, or active bowel obstruction. Caution is also advised for patients with significant hepatic impairment or those taking strong CYP3A4 inducers that may reduce drug efficacy.